fbpx Skip to main content

FRIDAY, Nov. 13, 2020 (HealthDay News) — In elderly adults, vitamin D supplementation, omega-3 supplementation, and strength training, individually or in combination, do not improve clinical outcomes, according to a study published in the Nov. 10 issue of the Journal of the American Medical Association.

Heike A. Bischoff-Ferrari, M.D., from the University Hospital Zurich, and colleagues conducted a double-blind, placebo-controlled, 2 x 2 x 2 factorial randomized clinical trial among 2,157 adults aged 70 years or older with no major health events in the previous five years. Participants were randomly assigned to three years of intervention in one of the following: 2,000 IU/day vitamin D3, 1 g/day omega-3, and a strength-training exercise program; vitamin D3 and omega-3; vitamin D3 and exercise; vitamin D3 alone; omega-3 and exercise; omega-3 alone; exercise alone; or placebo. The primary outcomes were change in systolic and diastolic blood pressure, the Short Physical Performance Battery, Montreal Cognitive Assessment, and incidence rates of nonvertebral fractures and infections during a three-year follow-up.

The researchers found that at three years, there were no statistically significant benefits for any interventions individually or in combination. Twenty-five deaths occurred, with similar numbers in all treatment groups.

“In this five-country European trial of 2,157 adults aged 70 years or older without major comorbidities, vitamin D, omega-3s, and a strength-training exercise program, individually or in combination, did not improve six primary health end points,” the authors write.

Several authors disclosed financial ties to pharmaceutical and nutrition companies, some of which provided funding for the study.

Abstract/Full Text (subscription or payment may be required)

You May Also Like::  AHA News: Stroke, Blindness, a Heart Transplant – And a Can-Do Spirit

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More